Vaccine policyPneumococcal vaccineImmunization scheduleImmunization programsStreptococcus pneumoniae bacteria causes substantial morbidity and mortality worldwide, especially in children under 5 years of age. Prevention of these outcomes by pneumococcal conjugate vaccines (PCV) is an important public health ...
The vaccine does not cover all strains of pneumococcal disease - there are more than 90 - but it does protect against the majority that result in serious illness in young children. Since its introduction, hospitalisations of children aged under six forinvasive pneumococcal diseasehave halved and t...
The standard schedule specifies eligibility for doses at 6, 10, and 14 weeks of age. The participants in each alternative schedule cluster who are assigned to the measurement of immunogenicity endpoints are further assigned to receive the YF vaccine co-administered at 9 months of age with the ...
At the moment, our study represents one of the very few sources of information regarding pneumococcal vaccine uptake among Italian citizens and at-risk categories. Uptake levels appear inadequate both among high-risk adults and children. Information on vaccine availability and accessibility of vaccination...
On the basis of these informations, the conjugate pneumococcal vaccine has been included in the recommended vaccination schedule in Belgium. However, repeated vaccine shortages as well as the high cost of the product make the implementation of this recommendation uncertain. 展开 ...
among children younger than 6 years. The Food and Drug Administration (FDA) recently approved the first protein-polysaccharide conjugate vaccine to prevent invasive pneumococcal diseases in infants and toddlers < 2 years of age. This conjugated vaccine against pneumococcus uses the same technology as ...
Pneumococcal 15-valent conjugate vaccine (PCV15; Vaxneuvance) or pneumococcal 20-valent conjugate vaccine (PCV20; Prevnar 20) for all children aged 2 through 23 months according to currently recommended PCV dosing and schedules; Children with an incomplete PCV vaccination status, use of either PC...
Pneumococcal polyvalent vaccine (Pneumovax 23, Pnu-Imune 23) is a vaccine used for individuals over the age of 50 years and children age 2 years or older who are at an increased risk for pneumococcal disease, and have no complicating medical issues. Side effects, drug interactions, dosing and...
Pneumonia is the leading single cause of mortality in children under the age of 5 years worldwide [1]. Many of these pneumonia related deaths are vaccine preventable. The global burden of disease of pneumococcal pneumonia is difficult to determine, particularly in developing countries with limited ...
Notably, few data were available, with only a single study comparing 3 + 0 to a 2 + 1 PCV10 dosing schedule in children in Nepal. We found no published studies comparing a 1+1 schedule with a 2 + 1 schedule for either vaccine formulation, although clinical trials are ...